Presented virtually at 24th North American ISSX Meeting, September 2021
Jingjing Yu,Yan Wang, Cheryl Wu, and Isabelle Ragueneau-Majlessi
Abstract
Patients with infectious diseases in low-income countries (LICs) are often at risk of pharmacokinetic (PK) drug-drug interactions (DDIs). To assist in silico mechanistic modeling and simulations to predict DDI liability and guide optimal management of DDIs, a knowledgebase of anti-infective drugs, specifically treatments for malaria and tuberculosis, has been established.